FDA Vioxx Documents Offer Case Study For “Drug Watch” Website
Executive Summary
The discussions between Merck and FDA regarding the best way to present safety data from the VIGOR trial in Vioxx labeling offer a case study in how the agency's new "Drug Watch" safety website may affect disclosure of risk information